Arq. Bras. Cardiol. 2023; 120(1): e20220670
Filipe Ferrari
, Anderson Donelli da Silveira
, Ricardo Stein
97
How to cite this article
Ferrari F, Silveira AD, Stein R. . Arq. Bras. Cardiol. 2023;120(1):e20220670.
Ferrari, Filipe; Silveira, Anderson Donelli da; Stein, Ricardo. . Arq. Bras. Cardiol., v. 120, n. 1, e20220670, Jan. 2023.
Ferrari, F., Silveira, A. D. , & Stein, R. (2023). . Arq. Bras. Cardiol., 120(1), e20220670.
Ferrari, Filipe and Silveira, Anderson Donelli da and Stein, Ricardo. . Arq. Bras. Cardiol. [online]. 2023, vol. 120, n. 1, [cited 2025-09-08], e20220670. Available from: <https://abccardiol.org/en/article/11758/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.